SCHEMBL30749047

SCHEMBL30749047

CCCCOc1ccc(N2C(=O)C3(CC3)c3cnc(CO)nc32)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
PABPC1 P11940 1/20 0.38
CYP2D6 P10635 5/20 0.38
CYP2C9 P11712 5/20 0.38
CYP3A4 P08684 4/20 0.38
LMNA P02545 3/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP19A1 P11511 4/20 0.36
THRB P10828 1/20 0.36
GAA P10253 1/20 0.36
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
METAP2 P50579 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21383375 0.62 HTT (0.51) PABPC1CYP2D6CYP2C9CYP3A4LMNA
SCHEMBL22864832 0.61 NR5A1 (0.51) PABPC1CYP2D6CYP2C9CYP3A4LMNA
SCHEMBL22864833 0.61 NR5A1 (0.51) PABPC1CYP2D6CYP2C9CYP3A4LMNA
SCHEMBL2997957 0.60 MGLL (0.62) PABPC1LMNAHTTSMN1; SMN2
SCHEMBL3003422 0.60 MGLL (0.62) PABPC1LMNAHTTSMN1; SMN2
SCHEMBL30404232 0.60 POLB (0.50) PABPC1CYP2D6CYP2C9CYP3A4LMNA
Alcohol SCHEMBL28398877 0.60 LTA4H (0.65) CYP2D6CYP3A4GAA
SCHEMBL13920879 0.59 CDC25A (0.57) PABPC1CYP2D6CYP2C9CYP3A4LMNA
SCHEMBL15060979 0.59 NOTUM (0.79) CYP2D6CYP2C9CYP3A4MAPTCYP19A1
SCHEMBL26850 0.58 LTA4H (0.70) CYP2D6CYP2C9CYP3A4SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT CCNE1 2310/4885CDK2 680/4885PABPC1 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.